IL4R and Alzheimer disease: Dupilumab, an interleukin 4 receptor alpha (IL-4Rα) antagonist was recently approved by FDA as a treatment for AD after it showed positive effects in patients with moderate to severe AD, with reduced blood type 2 signature, and reversed epidermal abnormalities9.